LEUPROLIDE ACETATE
Clinical safety rating: avoid
Contraindicated (not allowed)
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Upon continuous administration, it suppresses pituitary gonadotropin secretion by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently reducing sex steroid (testosterone and estrogen) production in the gonads.
| Metabolism | Leuprolide is a synthetic peptide that is metabolized via peptidase-mediated hydrolysis, primarily in the liver and kidneys. Enzymes involved include endopeptidases and exopeptidases. Less than 5% is excreted unchanged in urine. |
| Excretion | Renal: approximately 5% as unchanged drug; hepatic metabolism accounts for the majority of clearance, with metabolites excreted renally and fecally; biliary excretion is minimal. |
| Half-life | Terminal elimination half-life is approximately 3 hours following intravenous administration; after subcutaneous depot formulations, the effective half-life is extended due to slow release, with a terminal half-life of about 3-4 weeks for the 1-month depot. |
| Protein binding | Approximately 43-49% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 27-31 L (0.4 L/kg assuming 70 kg), indicating distribution into total body water. |
| Bioavailability | Short-acting subcutaneous injection: nearly 100%; depot intramuscular injection: approximately 90%; depot subcutaneous injection: approximately 90%. |
| Onset of Action | For short-acting subcutaneous injection, initial LH surge occurs within 1-2 hours; for depot intramuscular or subcutaneous injection, clinical suppression of testosterone or estradiol occurs within 2-4 weeks. |
| Duration of Action | For depot formulations, duration is dependent on the preparation: 1-month depot provides suppression for approximately 4 weeks; 3-month and 6-month depots provide suppression for 12 and 24 weeks, respectively. Continuous therapy maintains suppression; discontinuation leads to recovery of gonadal function typically within months. |
Prostate cancer: 7.5 mg IM once monthly or 22.5 mg IM once every 3 months or 45 mg SC once every 6 months. Central precocious puberty: 50 mcg/kg/day SC or 7.5 mg IM once monthly. Endometriosis: 3.75 mg IM once monthly or 11.25 mg IM once every 3 months.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment based on Child-Pugh classification. |
| Pediatric use | Central precocious puberty: Initial dose 50 mcg/kg/day SC; if inadequate suppression, increase by 10 mcg/kg/day; maximum 100 mcg/kg/day. Alternatively, IM leuprolide acetate depot 7.5 mg every 28 days for body weight ≥25 kg; 11.25 mg every 28 days for body weight <25 kg. |
| Geriatric use | No dose adjustment required; administer standard adult dosing. Monitor for potential increased sensitivity to cardiovascular effects and bone density loss. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Causes an initial increase in testosterone levels which may worsen symptoms in prostate cancer patients.
| Breastfeeding | It is unknown if leuprolide acetate is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy. The M/P ratio has not been determined. |
| Teratogenic Risk | Leuprolide acetate is contraindicated in pregnancy (Category X). There is a high risk of fetal loss and congenital anomalies when administered during pregnancy, particularly during the first trimester due to suppression of pituitary gonadotropins and potential disruption of early embryonic development. In animal studies, leuprolide caused increased fetal mortality and teratogenicity across all trimesters. |
■ FDA Black Box Warning
No FDA black box warning is required for leuprolide acetate; however, labeling includes warnings about tumor flare (transient increase in serum testosterone/estrogen) and an increased risk of diabetes, cardiovascular events, and stroke in men receiving GnRH agonists for prostate cancer.
| Common Effects | endometriosis |
| Serious Effects |
["Hypersensitivity to leuprolide acetate, GnRH agonists, or any component of the formulation","Pregnancy (category X: may cause fetal harm during initial stages; women of childbearing potential must use effective contraception)","Lactation (excreted in breast milk; potential for adverse effects in nursing infants)","Undiagnosed vaginal bleeding (in women)"]
| Precautions | ["Tumor flare: Transient worsening of symptoms (e.g., bone pain, urinary obstruction) during initial therapy in prostate cancer","Hyperglycemia and increased risk of diabetes mellitus","Cardiovascular risks: Myocardial infarction, sudden cardiac death, stroke (especially in men)","Bone loss: Decreased bone mineral density with prolonged use (osteoporosis, fracture risk)","Hypersensitivity reactions (angioedema, anaphylaxis)","Seizures have been reported in patients with epilepsy or underlying CNS disorders","Psychiatric effects (mood changes, depression)","Injection site reactions (pain, erythema, abscess)","Pituitary apoplexy (rare but serious, especially in patients with pituitary adenoma)","QT interval prolongation caution in patients with electrolyte abnormalities or on QT-prolonging drugs"] |
Loading safety data…
| Fetal Monitoring | Pregnancy testing must be performed prior to initiation of therapy to rule out pregnancy. If pregnancy is suspected during treatment, leuprolide should be discontinued immediately and the pregnancy evaluated. Ultrasound monitoring may be indicated to assess fetal viability and development if exposure occurs. |
| Fertility Effects | Leuprolide acetate suppresses pituitary gonadotropin secretion, leading to reversible inhibition of ovulation and spermatogenesis. Fertility is expected to return upon discontinuation of therapy, but the time to recovery may vary. In females, ovulation may resume after treatment ends; in males, testosterone levels and spermatogenesis typically recover within months. |